CTOs on the Move

Agility Health

www.agilityhealth.com

 
Agility Health is a leading healthcare provider devoted to the rehabilitation of our patients' physical injuries and conditions. Established in 1968, Agility Health delivers personalized care through over one million therapy visits annually at more than 155 service sites in 20 states nationwide. Our team is dedicated to providing exceptional value to the patients, clients and partners we serve. Through our innovative clinical services, proven practice management systems and flexible partnerships, we help achieve optimal performance in a variety of settings, including outpatient clinics, hospitals, long-term care facilities and employer work sites. Agility Health is one of the top 10 rehabilitation services ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Urovant

We aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity and compassion. We develop innovative therapies and participate in exceptional licensing opportunities. Our goal is to be the leading specialty company: recognized and trusted by patients and providers for our commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.

Equideum Health

Equideum Health creates Web3 person-centered healthcare and research networks to advance health equity and outcomes by optimizing data liquidity across enterprise and individual data silos, powered by Ethereum.

TechHealth

TechHealth is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Transcend Services

Transcend Services, Inc. (Transcend) provides medical transcription services to the healthcare industry. The Company provides two primary medical transcription options for customers: the provision of transcription services and technology using the